PPHM News Alert Peregrine Pharmaceuticals Inc (PPHM) 1.40 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Peregrine Pharmaceuticals Inc (PPHM) 1.40 $PPHM

Peregrine Pharmaceuticals Down 6.1%, Shares Slide into the Red (PPHM)
Comtex SmarTrend(R) - Mon Dec 15, 12:42PM CST
Peregrine Pharmaceuticals (NASDAQ PHM) is one of today's worst performing low-priced stocks, down 6.1% to $1.39 on 1.0x average daily volume. Peregrine Pharmaceuticals has traded 700,000 shares thus far today, vs. average volume of 696,000 shares per day. The stock has underperformed the Dow (-6.1% to the Dow's -0.5%) and underperformed the S&P 500 (-6.1% to the S&P's -0.4%) during today's trading.
PPHM: 1.40 (+0.01)

Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Marketwired - Fri Dec 12, 7:00AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, today announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13, 2014.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Peregrine Pharma FQ2 results
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 5:47AM CST

PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Dec 11, 3:39AM CST

PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Dec 10, 3:25PM CST

PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 3:04PM CST

PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwired - Wed Dec 10, 3:02PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, today announced financial results for the second quarter of fiscal year (FY) 2015 ended October 31, 2014. The company also provided an update on its advancing clinical pipeline and reviewed other corporate developments.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Marketwired - Wed Dec 10, 7:06AM CST
Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Wed Dec 10, 6:11AM CST
The board of directors of Peregrine Pharmaceuticals (NASDAQ PHM) (NASDAQ PHMP), a biopharmaceutical company, declared on Tuesday its quarterly dividend of USD0.65625 per share of its 10.50% Series E convertible preferred stock.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:35PM CST

SIGM: 5.58 (+0.06), RH: 96.97 (-0.16), MW: 43.78 (-0.24), IRET: 8.46 (-0.11), CENT: 8.66 (+0.06), AVNW: 1.52 (+0.01), WTSL: 0.06 (-0.02), PPHM: 1.40 (+0.01), CASY: 89.15 (+0.12), SURG: 4.39 (-0.03)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwired - Tue Dec 09, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock" .
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Peregrine reports December 10
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 3:26PM CST

PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
Marketwired - Wed Dec 03, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year (FY) 2015 ended October 31, 2014 on December 10, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Standard Time (4:30 PM Eastern Standard Time). Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 6.49 (+0.29), AGEN: 3.85 (unch), NVAX: 5.81 (+0.18), ALXN: 181.96 (+3.09), PPHM: 1.40 (+0.01), THLD: 2.93 (+0.01), GSK: 42.85 (+0.11), OMER: 22.09 (+0.48)

Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer
Marketwired - Mon Nov 10, 6:31AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting and Associated Programs. This conference was held November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland. The translational clinical presentation titled: "Correlative Studies of a Phase II Clinical Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)" was presented Saturday.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma
Marketwired - Fri Nov 07, 6:45AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the first of four presentations of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. Data from today's presentation show that the combination of a phosphatidylserine (PS)-targeting antibody equivalent to bavituximab and an antibody targeting the immune checkpoint CTLA-4 yielded statistically significant anti-tumor effects as compared to the anti-CTLA-4 antibody alone. In addition, this combination decreased levels of Arg1, a molecule predominantly expressed by myeloid derived suppressor cells (MDSC) and M2 macrophages; two key cell types that contribute to immunosupressive activity in animal models of melanoma. This presentation will be made at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting and Associated Programs being held November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer
Marketwired - Thu Oct 30, 8:42AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of data from the Phase Ib investigator-sponsored trial (IST) of its immunotherapy bavituximab in combination with the chemotherapies pemetrexed and carboplatin in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Data from this single-arm, open-label, multi-center trial show an overall tumor response (ORR) of 35%, a median progression-free-survival (PFS) of 4.8 months, and a median overall survival (OS) of 12.2 months. Favorable trends in ORR and OS continue to support bavituximab's potential in NSCLC.(1-4) These data are presented in a poster session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology being held at the Marriott Downtown Chicago Magnificent Mile in Chicago, Illinois.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)

Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells
PR Newswire - Fri Oct 24, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: CytRx Corporation (NASDAQ: CYTR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index advancing 3.42% in the previous three months. Register for your complimentary reports on these five stocks at:
VRTX: 115.15 (+1.40), STEM: 0.90 (+0.03), ALXN: 181.96 (+3.09), CYTR: 2.58 (+0.03), PPHM: 1.40 (+0.01)

Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:39AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) was a big mover last session, as its shares rose nearly 11% on the day.
MACK: 10.91 (+0.36), MYGN: 36.50 (+0.28), HALO: 9.34 (+0.31), PPHM: 1.40 (+0.01)

Nasdaq stocks posting largest volume increases
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CHFN: 11.36 (-0.07), ARTW: 4.97 (+0.02), PPHM: 1.40 (+0.01), PENX: 18.83 (+0.04), LAKE: 8.94 (+0.07), EXAC: 22.68 (+0.24), NAUH: 2.93 (+0.11), COVS: 2.73 (+0.08), UPIP: 1.05 (+0.03), JAXB: 12.26 (+0.96), CEMI: 3.98 (+0.08), DENN: 9.96 (+0.05)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 58

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading

Top 5 Most Recently Viewed Articles

Freddie Mac's 30-Year Mortgage Rate Decreases Slightly

Updated Category News Views 219

Freddie Mac Reports on Mortgage Rates In recent reports from Freddie Mac, there's good news for potential homebuyers. The 30-year fixed-rate mortgage (FRM) has seen a slight decline, which is a welcome change in a fluctuating market. This current value sits at an average of 6.64%, reflecting a small drop from the previous week's average of 6.65%. Understanding the Current...

Continue Reading
Sports.com Partners with SEGG Media for Soccerex Event

Updated Category News Views 251

Sports.com Joins SEGG Media as Title Sponsor at Soccerex Miami 2025 MIAMI BEACH, Fla. — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) has officially announced that Sports.com will take on the role of Title Sponsor for the engaging Soccerex Miami event happening at the Miami Beach Convention Center. This sponsorship reflects a significant commitment to promoting...

Continue Reading
Gastech 2025: A Global Convergence for Energy Innovations

Updated Category News Views 249

Gastech 2025 Unites the World of Energy Innovation Gastech 2025 welcomes more than 50,000 attendees from over 150 countries, establishing Milan as the global center for critical dialogues on energy supply, transformation, and innovation. This event has become a vital platform for high-level conversations that shape the future of energy. Leadership at Gastech 2025...

Continue Reading
Baird Confirms Outperform Rating for Costco Amidst Strong Growth

Updated Category News Views 68

Strong Sales Performance Driving Costco's Success Baird has reaffirmed its Outperform rating for Costco Wholesale (NASDAQ: COST), while upholding a price target of $975. The firm's latest insights indicate that Costco's global core comparable sales, excluding gas and foreign exchange influences, have surged by 8.9%. Such a rise is significant and demonstrates the...

Continue Reading
Celebrating a Decade of DNBSEQ™: Innovations and Impact

Updated Category News Views 290

Celebrating a Decade of DNBSEQ™ Technology MGI Tech Co., Ltd. (NASDAQ: MGI) is thrilled to celebrate ten years of its revolutionary DNBSEQ™ sequencing technology. This milestone marks a significant journey in transforming the landscape of genomics, offering solutions that not only enhance scientific research but also make genomic information more accessible to a...

Continue Reading